Takayuki Tabayashi

Kawagoe, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Resolution of the Asian Paradox and the molecular synergy of CD5/CD6-ALCAM axis and BCL2 in driving CNS tropism in DLBCL.

Resolution of the Asian Paradox and the molecular synergy of CD5/CD6-ALCAM axis and BCL2 in driving CNS tropism in DLBCL.

Journal: Leukemia & lymphoma

Published: June 01, 2026

Mosunetuzumab for relapsed follicular lymphoma presenting with chylothorax: A case report and literature review.

Mosunetuzumab for relapsed follicular lymphoma presenting with chylothorax: A case report and literature review.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: May 24, 2026

CD83 as a novel prognostic biomarker for diffuse large B-cell lymphoma arising in immune deficiency/dysregulation among rheumatoid arthritis patients treated with methotrexate.

CD83 as a novel prognostic biomarker for diffuse large B-cell lymphoma arising in immune deficiency/dysregulation among rheumatoid arthritis patients treated with methotrexate.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: April 01, 2026

Primary central nervous system T cell lymphoma involving multiple brain and spinal cord lesions with SETD2 mutation.

Primary central nervous system T cell lymphoma involving multiple brain and spinal cord lesions with SETD2 mutation.

Journal: International journal of hematology

Published: January 15, 2026

Complexity and Challenges of Translating the Dark Zone Signature Into Immunohistochemistry in Diffuse Large B-Cell Lymphoma.

Complexity and Challenges of Translating the Dark Zone Signature Into Immunohistochemistry in Diffuse Large B-Cell Lymphoma.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: December 30, 2025

Long-term efficacy and safety of romiplostim plus immunosuppressive therapy as first-line treatment in patients with aplastic anaemia: 2-year interim analysis of observational study of two clinical trials.

Long-term efficacy and safety of romiplostim plus immunosuppressive therapy as first-line treatment in patients with aplastic anaemia: 2-year interim analysis of observational study of two clinical trials.

Journal: British journal of haematology

Published: December 05, 2025

Significance and Utility of Immunohistochemical MTAP Expression to Predict CDKN2A Genomic Status in Diffuse Large B-Cell Lymphoma.

Significance and Utility of Immunohistochemical MTAP Expression to Predict CDKN2A Genomic Status in Diffuse Large B-Cell Lymphoma.

Journal: Pathology international

Published: October 24, 2025

Systemic, asymptomatic skeletal muscle infiltration by MALT lymphoma: Defining a 'silent infiltrator' phenotype with 18F-FDG PET/CT.

Systemic, asymptomatic skeletal muscle infiltration by MALT lymphoma: Defining a 'silent infiltrator' phenotype with 18F-FDG PET/CT.

Journal: Leukemia research reports

Published: October 14, 2025

Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia.

Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia.

Journal: International journal of hematology

Published: September 03, 2025

Comparison of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Primary Plasma Cell Leukemia in Japan.

Comparison of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Primary Plasma Cell Leukemia in Japan.

Journal: Transplantation and cellular therapy

Published: June 24, 2025

Genetic Profiling Reveals the Distinctions Among MTX-Associated DLBCL, EBV-Positive Mucocutaneous Ulcer, and EBV + DLBCL.

Genetic Profiling Reveals the Distinctions Among MTX-Associated DLBCL, EBV-Positive Mucocutaneous Ulcer, and EBV + DLBCL.

Journal: Cancer science

Published: April 03, 2025

The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Journal: Cardio-oncology (London, England)

Published: February 13, 2025

Showing 1-12 of 41

Last Updated: 09/26/2026